Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Bristol-Myers Squibb Company Revenue & Financial Statements
Bristol-Myers Squibb Company reported revenue of $48.2B for the fiscal year ended December 31, 2025, down 0.2% year over year, with net income of $7.1B and diluted EPS of $3.46.
- Company
- Bristol-Myers Squibb Company BMY · NYSE
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 46.4B | 46.2B | 45.0B | 48.3B | 48.2B |
| Cost of revenue | 9.9B | 10.1B | 10.7B | 14.0B | 13.9B |
| Gross profit | 36.4B | 36.0B | 34.3B | 34.3B | 34.3B |
| Operating income | — | — | — | — | — |
| Pretax income | 6.5B | 7.9B | 5.8B | 6.5B | 9.3B |
| Net income | 7.6B | 6.3B | 7.8B | (8.6B) | 7.1B |
| Diluted EPS | 3.12 | 2.95 | 3.86 | -4.41 | 3.46 |
| EBITDA | — | — | — | — | — |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.9B | 12.2B | 11.9B | 12.3B | 11.2B | 12.3B | 12.2B | 12.5B |
| Cost of revenue | 2.9B | 3.3B | 3.0B | 4.8B | 3.0B | 3.4B | 3.4B | 4.1B |
| Gross profit | 8.9B | 8.9B | 8.9B | 7.5B | 8.2B | 8.9B | 8.8B | 8.4B |
| Operating income | — | — | — | — | — | — | — | — |
| Pretax income | (11.5B) | — | — | — | 3.0B | 1.8B | 3.1B | 1.5B |
| Net income | (11.8B) | 1.6B | 1.2B | 302.0M | 2.3B | 1.2B | 2.2B | 1.1B |
| Diluted EPS | -5.89 | 0.83 | 0.60 | 0.04 | 1.20 | 0.64 | 1.08 | 0.53 |
| EBITDA | — | — | — | — | — | — | — | — |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2024 | FY2024 | FY2025 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Total assets | — | 92.6B | — | 90.0B | — |
| Current assets | — | 29.8B | — | 29.4B | — |
| Cash & equivalents | — | 10.3B | — | 10.2B | — |
| Total liabilities | — | 76.2B | — | 71.5B | — |
| Current liabilities | — | 23.8B | — | 23.4B | — |
| Long-term debt | — | 47.6B | — | 42.9B | — |
| Total debt | — | 49.6B | — | 45.1B | — |
| Stockholders’ equity | — | 16.3B | — | 18.5B | — |
| Net debt | — | 39.3B | — | 34.9B | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 16.2B | 13.1B | 13.9B | 15.2B | 14.2B |
| Investing cash flow | (538.0M) | (1.1B) | (2.3B) | (21.4B) | (4.1B) |
| Financing cash flow | (16.2B) | (17.0B) | (9.4B) | 5.1B | (10.3B) |
| Capital expenditure | 973.0M | 1.1B | 1.2B | 1.2B | 1.3B |
| Free cash flow | 15.2B | 11.9B | 12.7B | 13.9B | 12.8B |
| Dividends paid | 4.4B | 4.6B | 4.7B | 4.9B | 5.0B |
| Stock-based compensation | 583.0M | 457.0M | 518.0M | 507.0M | 553.0M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every BMY filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.